Review
Published on 13 Apr 2022
Adalimumab in Pediatric Inflammatory Bowel Disease
in Pediatric Gastroenterology, Hepatology and Nutrition
Frontiers in Pediatrics
doi 10.3389/fped.2022.852580
- 9,735 views
- 7 citations
34 articles related to "Infliximab Ifx"
Articles
Original Research
Published on 05 May 2017
Characterization of CD4 T Cell Epitopes of Infliximab and Rituximab Identified from Healthy Donors
in Vaccines and Molecular Therapeutics
Frontiers in Immunology
doi 10.3389/fimmu.2017.00500
- 14,584 views
- 81 citations
Brief Research Report
Accepted on 02 Mar 2026
Cinical Characteristics of Patients with Ulcerative Colitis During Biologic therapy and Analysis of Risk Factors for Concurrent Clostridioides difficile Infection
in Bacteria and Host
Frontiers in Cellular and Infection Microbiology
Review
Published on 25 Nov 2024
Acute severe ulcerative colitis: using JAK-STAT inhibitors for improved clinical outcomes
in Therapy in Gastroenterology
Frontiers in Gastroenterology
doi 10.3389/fgstr.2024.1488288
- 3,837 views
Original Research
Published on 27 Apr 2022
A Novel Neutrophil-Based Biomarker to Monitor Disease Activity and Predict Response to Infliximab Therapy in Patients With Ulcerative Colitis
in Gastroenterology
Frontiers in Medicine
doi 10.3389/fmed.2022.872831
- 4,121 views
- 12 citations
Original Research
Published on 12 Mar 2024
C-reactive protein-to-albumin ratio and neutrophil-to-albumin ratio for predicting response and prognosis to infliximab in ulcerative colitis
in Gastroenterology
Frontiers in Medicine
doi 10.3389/fmed.2024.1349070
- 3,670 views
- 7 citations
Original Research
Published on 04 Mar 2022
Clinical Significance of Novel Neutrophil-Based Biomarkers in the Diagnosis and Prediction of Response to Infliximab Therapy in Crohn’s Disease
in Autoimmune and Autoinflammatory Disorders
Frontiers in Immunology
doi 10.3389/fimmu.2022.865968
- 4,484 views
- 13 citations
Original Research
Published on 08 Dec 2025
Concentration monitoring and dose optimization for infliximab in Crohn’s disease patients: a machine learning-based covariate ensemble model
in Systems Immunology
Frontiers in Immunology
doi 10.3389/fimmu.2025.1715241
- 1,548 views
Original Research
Published on 13 Jun 2022
Proteomic Analysis of Potential Targets for Non-Response to Infliximab in Patients With Ulcerative Colitis
in Gastrointestinal and Hepatic Pharmacology
Frontiers in Pharmacology
doi 10.3389/fphar.2022.905133
- 5,218 views
- 5 citations
Original Research
Published on 20 Oct 2025
CT-Based assessment of sarcopenia and its association with biologic treatment outcomes in Chinese Children with Crohn's disease
in Clinical Nutrition
Frontiers in Nutrition
doi 10.3389/fnut.2025.1660731
- 1,638 views
Original Research
Published on 12 Jul 2022
Serological Biomarkers of Intestinal Collagen Turnover Identify Early Response to Infliximab Therapy in Patients With Crohn’s Disease
in Gastroenterology
Frontiers in Medicine
doi 10.3389/fmed.2022.933872
- 3,278 views
- 14 citations
Original Research
Published on 16 May 2025
Switching from intravenous to subcutaneous infliximab in patients with immune mediated diseases in clinical remission
in Gastroenterology
Frontiers in Medicine
doi 10.3389/fmed.2025.1583401
- 3,722 views
- 3 citations
Original Research
Published on 20 Nov 2024
Corticosteroids combined with infliximab vs. corticosteroids sequential infliximab for acute severe ulcerative colitis with mucosal deficiency: a retrospective study
in Gastroenterology
Frontiers in Medicine
doi 10.3389/fmed.2024.1442519
- 1,878 views
Original Research
Published on 14 Aug 2023
The impact of medication belief on adherence to infliximab in patients with Crohn’s disease
in Drugs Outcomes Research and Policies
Frontiers in Pharmacology
doi 10.3389/fphar.2023.1185026
- 3,050 views
- 8 citations
Original Research
Published on 03 Jan 2022
Derlin-1, as a Potential Early Predictive Biomarker for Nonresponse to Infliximab Treatment in Rheumatoid Arthritis, Is Related to Autophagy
in Autoimmune and Autoinflammatory Disorders
Frontiers in Immunology
doi 10.3389/fimmu.2021.795912
- 4,746 views
- 9 citations
Study Protocol
Published on 19 Sep 2024
Comparison of ustekinumab, infliximab and combination therapy in moderately to severely active ulcerative colitis – a study protocol of a randomized, multicenter, head-to-head COMBO-UC trial
in Gastroenterology
Frontiers in Medicine
doi 10.3389/fmed.2024.1458998
- 6,250 views
- 5 citations